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The objective of this study is to deliver anti-pPKCθ (T538) into T cells (hPBMCs) by using cell 
penetrating peptide mimics (CPPMs) to neutralize PKCθ activity both in vitro and in vivo, with 
the eventual goal of treating aplastic anemia (AA). AA is an immune-mediated bone marrow 
failure disease caused by T helper type 1 (Th1) autoimmune responses, which destroy blood 
cell progenitors. It was previously reported that protein kinase C theta (PKCθ), expressed 
specifically in T cells, plays an important role in T cell signaling by mediating Th1 differentiation. 
Mice treated with Rottlerin, a pharmacological inhibitor of PKCθ, are rescued from the disease 
when PKCθ phosphorylation was inhibited. Furthermore, humanized antibodies are increasingly 
gaining attention as therapies. The delivery of antibodies could be achieved via cell penetrating 
peptides (CPPs), which are able to internalize cargo into cells. Here, we designed, synthesized 
and characterized CPPMs to increase delivery efficiency of an antibody against phosphorylated 
PKCθ (T538), which subsequently interfered with the function of the kinase. We designed an in 
vitro delivery method for the CPPM/Anti-pPKCθ complex then assessed T cell activation and AA 
disease marker expression. Also, we generated an in vivo humanized mouse model of AA and 
tested the complex for delivery and effect on survival of these mice. Altogether the results reveal 
that PKCθ may be an optimal target for bone marrow failure treatment and intracellular antibody 
delivery may represent a novel approach for AA treatment. 
 
